The integrated 31-gene expression profile test identifies low-risk patients with cutaneous melanoma who can forego the SLNB procedure: results from a prospective, multicenter trial

Q: What type of study is this?

This is a Cohort Study study (also classified as: Human Clinical Trial).

Timothy L. Beard; J. Michael Guenther; Stanley P. Leong; Maki Yamamoto; Samuel Dierks; Brenda Sickle-Santanello; A. Milford Ward; Mark Cripe; Parth Shah; Shawn E. Young

doi:10.1080/14796694.2026.2640227

March 13, 2026Future Oncology

The integrated 31-gene expression profile test identifies low-risk patients with cutaneous melanoma who can forego the SLNB procedure: results from a prospective, multicenter trial

View at Publisher

Ask AI

Bookmark

Share

Key Points

The study aimed to determine if a gene expression profile can predict SLN positivity in melanoma patients.
Conducted a multicenter prospective trial
Evaluated 31-gene expression profile test in melanoma patients
Assessed SLN positivity and recurrence-free survival (RFS) outcomes
The gene expression profile test accurately predicted SLN positivity
Patients who avoided SLNB had high recurrence-free survival (RFS)
Identified a subset of low-risk melanoma patients

Ask about this paper

Answers are grounded in this paper and cite their sources.

Implication

Prospective trial shows gene expression profile predicts SLN positivity in melanoma, indicating a potential for avoiding SLNB.

Abstract

In this multi-center prospective study, the i31-SLNB accurately predicted SLN positivity, and patients who avoided SLNB based on i31-SLNB results had high RFS. Thus, the i31-SLNB identifies low-risk patients who may consider foregoing the SLNB procedure.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Beard et al. (2026) studied this question.

synapsesocial.com/papers/69b5ff5c83145bc643d1bbf4 https://doi.org/10.1080/14796694.2026.2640227

View at Publisher

Ask AI

Bookmark

Share

The integrated 31-gene expression profile test identifies low-risk patients with cutaneous melanoma who can forego the SLNB procedure: results from a prospective, multicenter trial

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

The integrated 31-gene expression profile test identifies low-risk patients with cutaneous melanoma who can forego the SLNB procedure: results from a prospective, multicenter trial

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading